SHARON WERTH: Open Payments
NPI 1093390635 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 37 payments from 10 companies in 2025. Trend: 2023 $724 · 2024 $467 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $209 |
| Amgen Inc. | 10 | $187 |
| Axsome Therapeutics, Inc. | 3 | $89 |
| ABBVIE INC. | 3 | $58 |
| PFIZER INC. | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| ABIOMED | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
Products named: REPATHA, Rybelsus, Wegovy, Symbravo, Ozempic, OTEZLA, UBRELVY, ELIQUIS.
Industry payments across TX — which companies pay providers there.
